Patents by Inventor Eleni Dokou

Eleni Dokou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
    Patent number: 11951212
    Abstract: The present invention features compositions comprising a plurality of therapeutic agents wherein the presence of one therapeutic agent enhances the properties of at least one other therapeutic agent. In one embodiment, the therapeutic agents are cystic fibrosis transmembrane conductance regulators (CFTR) such as a CFTR corrector or CFTR potentiator for the treatment of CFTR mediated diseases such as cystic fibrosis. Methods and kits thereof are also disclosed.
    Type: Grant
    Filed: March 17, 2021
    Date of Patent: April 9, 2024
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Brian Dean Phenix, Laurent Jean-Claude Bagnol, Geoffrey Glen Brodeur, Sachin Chandran, Eleni Dokou, Lori Ann Ferris, Dragutin Knezic, Katie Lynn McCarty, Ales Medek, Sara A. Waggener
  • Pharmaceutical composition and administrations thereof
    Patent number: 11752106
    Abstract: The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.
    Type: Grant
    Filed: September 15, 2021
    Date of Patent: September 12, 2023
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Eleni Dokou, Shahla Jamzad, John P. Caesar, Jr., Majed Fawaz, Laura Das, Chong-Hui Gu, Patricia Nell Hurter, Meghna Jai Israni, Meghan M. Johnston, Dragutin Knezic, Andrew G. Kuzmission, HongRen Wang
  • PHARMACEUTICAL COMPOSITIONS FOR TREATING CYSTIC FIBROSIS
    Publication number: 20220257564
    Abstract: A pharmaceutical composition comprising Compound I: Methods of treating cystic fibrosis comprising administering one or more of such pharmaceutical compositions to a patient.
    Type: Application
    Filed: September 15, 2021
    Publication date: August 18, 2022
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Cathy Chu, Varsha Dhamankar, Eleni Dokou, Eric L. Haseltine, Samuel Moskowitz, Sarah Robertson, David Waltz, Weichao George Chen
  • PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF
    Publication number: 20220241206
    Abstract: The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.
    Type: Application
    Filed: September 15, 2021
    Publication date: August 4, 2022
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Eleni DOKOU, Shahla JAMZAD, John P. CAESAR, JR., Majed FAWAZ, Laura DAS, Chong-Hui GU, Patricia Nell HURTER, Meghna Jai ISRANI, Meghan M. JOHNSTON, Dragutin KNEZIC, Andrew G. KUZMISSION, HongRen WANG
  • Pharmaceutical compositions for treating cystic fibrosis
    Patent number: 11179367
    Abstract: A pharmaceutical composition comprising Compound I: Methods of treating cystic fibrosis comprising administering one or more of such pharmaceutical compositions to a patient.
    Type: Grant
    Filed: February 4, 2019
    Date of Patent: November 23, 2021
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Cathy Chu, Varsha Dhamankar, Eleni Dokou, Eric L. Haseltine, Samuel Moskowitz, Sarah Robertson, David Waltz, Weichao George Chen
  • Crystalline forms and compositions of CFTR modulators
    Patent number: 11155533
    Abstract: Crystalline Forms of Compound I: and pharmaceutically acceptable salts thereof are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.
    Type: Grant
    Filed: March 25, 2020
    Date of Patent: October 26, 2021
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Varsha Dhamankar, Kirk Raymond Dinehart, Eleni Dokou, Lori Ann Ferris, Nishanth Gopinathan, Katie McCarty, Catherine Metzler, Beili Zhang, Samuel Moskowitz, Sarah Robertson, David Waltz, Eric L. Haseltine, Weichao George Chen
  • Pharmaceutical composition and administrations thereof
    Patent number: 11147770
    Abstract: The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: October 19, 2021
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Eleni Dokou, Shahla Jamzad, John P. Caesar, Jr., Majed Fawaz, Laura Das, Chong-Hui Gu, Patricia Nell Hurter, Meghna Jai Israni, Meghan M. Johnston, Dragutin Knezic, Andrew G. Kuzmission, Hongren Wang
  • PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES
    Publication number: 20210308053
    Abstract: The present invention features compositions comprising a plurality of therapeutic agents wherein the presence of one therapeutic agent enhances the properties of at least one other therapeutic agent. In one embodiment, the therapeutic agents are cystic fibrosis transmembrane conductance regulators (CFTR) such as a CFTR corrector or CFTR potentiator for the treatment of CFTR mediated diseases such as cystic fibrosis. Methods and kits thereof are also disclosed.
    Type: Application
    Filed: March 17, 2021
    Publication date: October 7, 2021
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Brian Dean Phenix, Laurent Jean-Claude Bagnol, Geoffrey Glen Brodeur, Sachin Chandran, Eleni Dokou, Lori Ann Ferris, Dragutin Knezic, Katie Lynn McCarty, Ales Medek, Sara A. Waggener
  • COMPOSITIONS FOR TREATING CYSTIC FIBROSIS
    Publication number: 20210228489
    Abstract: A single tablet comprising Compound I. Methods of treating cystic fibrosis comprising administering one or more of such single tablets to a patient.
    Type: Application
    Filed: December 4, 2018
    Publication date: July 29, 2021
    Inventors: Eleni Dokou, Briana Lauziere, Kirk A. Overhoff
  • Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
    Patent number: 10980746
    Abstract: The present invention features compositions comprising a plurality of therapeutic agents wherein the presence of one therapeutic agent enhances the properties of at least one other therapeutic agent. In one embodiment, the therapeutic agents are cystic fibrosis transmembrane conductance regulators (CFTR) such as a CFTR corrector or CFTR potentiator for the treatment of CFTR mediated diseases such as cystic fibrosis. Methods and kits thereof are also disclosed.
    Type: Grant
    Filed: December 26, 2018
    Date of Patent: April 20, 2021
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Brian Dean Phenix, Laurent Jean-Claude Bagnol, Geoffrey Glen Brodeur, Sachin Chandran, Eleni Dokou, Lori Ann Ferris, Dragutin Knezic, Katie Lynn McCarty, Ales Medek, Sara A. Waggener
  • COMPOSITIONS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS
    Publication number: 20210069174
    Abstract: Compositions comprising Compound I of the formula (I) and methods of treating cystic fibrosis comprising administering Compound I. Compositions comprising a pharmaceutically acceptable salt of Compound I and methods of treating cystic fibrosis comprising administering a pharmaceutically acceptable salt of Compound I.
    Type: Application
    Filed: June 29, 2018
    Publication date: March 11, 2021
    Inventors: Cathy Chu, Eleni Dokou, Eric L. Haseltine, Samuel Moskowitz, Kirk A. Overhoff, Sarah Robertson, David Waltz
  • CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS
    Publication number: 20200392109
    Abstract: Crystalline Forms of Compound I: and pharmaceutically acceptable salts thereof are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.
    Type: Application
    Filed: March 25, 2020
    Publication date: December 17, 2020
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Varsha Dhamankar, Kirk Raymond Dinehart, Eleni Dokou, Lori Ann Ferris, Nishanth Gopinathan, Katie McCarty, Catherine Metzler, Beili Zhang, Samuel Moskowitz, Sarah Robertson, David Waltz, Eric L. Haseltine, Weichao George Chen
  • Crystalline forms and compositions of CFTR modulators
    Patent number: 10654829
    Abstract: Crystalline Forms of Compound I: and pharmaceutically acceptable salts thereof are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: May 19, 2020
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Varsha Dhamankar, Kirk Raymond Dinehart, Eleni Dokou, Lori Ann Ferris, Nishanth Gopinathan, Katie McCarty, Catherine Metzler, Beili Zhang, Samuel Moskowitz, Sarah Robertson, David Waltz, Eric L. Haseltine, Weichao George Chen
  • PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF
    Publication number: 20190274959
    Abstract: The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.
    Type: Application
    Filed: March 12, 2019
    Publication date: September 12, 2019
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Eleni DOKOU, Shahla JAMZAD, John P. CAESAR, JR., Majed FAWAZ, Laura DAS, Chong-Hui GU, Patricia Nell HURTER, Meghna Jai ISRANI, Meghan M. JOHNSTON, Dragutin KNEZIC, Andrew G. KUZMISSION, HongRen WANG
  • PHARMACEUTICAL COMPOSITIONS FOR TREATING CYSTIC FIBROSIS
    Publication number: 20190240197
    Abstract: A pharmaceutical composition comprising Compound I: Methods of treating cystic fibrosis comprising administering one or more of such pharmaceutical compositions to a patient.
    Type: Application
    Filed: February 4, 2019
    Publication date: August 8, 2019
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Cathy Chu, Varsha Dhamankar, Eleni Dokou, Eric L. Haseltine, Samuel Moskowitz, Sarah Robertson, David Waltz, Weichao George Chen
  • PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES
    Publication number: 20190125674
    Abstract: The present invention features compositions comprising a plurality of therapeutic agents wherein the presence of one therapeutic agent enhances the properties of at least one other therapeutic agent. In one embodiment, the therapeutic agents are cystic fibrosis transmembrane conductance regulators (CFTR) such as a CFTR corrector or CFTR potentiator for the treatment of CFTR mediated diseases such as cystic fibrosis. Methods and kits thereof are also disclosed.
    Type: Application
    Filed: December 26, 2018
    Publication date: May 2, 2019
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Brian Dean Phenix, Laurent Jean-Claude Bagnol, Geoffrey Glen Brodeur, Sachin Chandran, Eleni Dokou, Lori Ann Ferris, Dragutin Knezic, Katie Lynn McCarty, Ales Medek, Sara A. Waggener
  • Pharmaceutical composition and administrations thereof
    Patent number: 10272046
    Abstract: The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: April 30, 2019
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Eleni Dokou, Shahla Jamzad, John P. Caesar, Jr., Majed Fawaz, Laura Das, Chong-Hui Gu, Patricia Nell Hurter, Meghna Jai Israni, Meghan M. Johnston, Dragutin Knezic, Andrew G. Kuzmission, HongRen Wang
  • CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS
    Publication number: 20190119253
    Abstract: Crystalline Forms of Compound I: and pharmaceutically acceptable salts thereofare disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.
    Type: Application
    Filed: October 19, 2018
    Publication date: April 25, 2019
    Applicant: Vertex Pharamceuticals Incorporated
    Inventors: Varsha Dhamankar, Kirk Raymond Dinehart, Eleni Dokou, Lori Ann Ferris, Nishanth Gopinathan, Katie McCarty, Catherine Metzler, Beili Zhang
  • Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
    Patent number: 10206877
    Abstract: The present invention features compositions comprising a plurality of therapeutic agents wherein the presence of one therapeutic agent enhances the properties of at least one other therapeutic agent. In one embodiment, the therapeutic agents are cystic fibrosis transmembrane conductance regulators (CFTR) such as a CFTR corrector or CFTR potentiator for the treatment of CFTR mediated diseases such as cystic fibrosis. Methods and kits thereof are also disclosed.
    Type: Grant
    Filed: April 14, 2015
    Date of Patent: February 19, 2019
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Brian Dean Phenix, Laurent Jean-Claude Bagnol, Geoffrey Glen Brodeur, Sachin Chandran, Eleni Dokou, Lori Ann Ferris, Dragutin Knezic, Katie Lynn McCarty, Ales Medek, Sara A. Waggener
  • PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF
    Publication number: 20170100340
    Abstract: The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.
    Type: Application
    Filed: June 13, 2016
    Publication date: April 13, 2017
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Eleni DOKOU, Shahla JAMZAD, John P. CAESAR, JR., Majed FAWAZ, Laura DAS, Chong-Hui GU, Patricia Nell HURTER, Meghna Jai ISRANI, Meghan M. JOHNSTON, Dragutin KNEZIC, Andrew G. KUZMISSION, HongRen WANG